How fast will I lose weight on GLP-1s and is it sustainable?

Short answer

• Many people lose noticeable weight within weeks on GLP‑1s; typical clinical‑trial results are roughly 10–20% body‑weight loss after about 9–12 months, but results vary a lot.
• Weight is often regained if the drug is stopped and no durable lifestyle or medical plan is in place — long‑term therapy or continued behavior change is usually needed for sustained weight loss.

How fast you can expect to lose weight

• First 4–12 weeks: appetite suppression and reduced food intake produce the fastest change — some people lose several pounds (kg) per month early on. Initial loss also includes water and glycogen.
• 3–6 months: many people will have lost ~5–10% of starting body weight.
• 9–12 months (trial endpoints): in randomized trials, semaglutide (Wegovy) produced mean weight loss in the mid‑teens percent range (around 10–15% at ~68 weeks), while tirzepatide (Zepbound in weight‑management labeling; Mounjaro for diabetes) produced larger mean losses in some SURMOUNT trials (high‑dose tirzepatide groups showed mean losses into the high teens to low‑20s percent range at ~72 weeks). Individual responses vary — some lose much more, others less.

Why responses differ

• Dose and medication (liraglutide, semaglutide, tirzepatide differ in potency and dosing).
• Starting weight, metabolism, genetics, age, sex, and whether you have diabetes.
• Adherence, how quickly doses are escalated, accompanying diet/exercise, other medications.
• Side effects can limit tolerable dose for some people.

Is it sustainable?

• Stopping the drug commonly leads to weight regain because appetite and metabolic adaptations return toward baseline. Long‑term trials and clinical experience show weight is usually maintained only while the medication (or an alternative long‑term strategy) is continued.
• Sustainable approaches combine medication (if appropriate) with structured lifestyle change: calorie quality, regular physical activity, behavioral therapy, sleep and stress management. Some people use a medication taper/alternation strategy under medical supervision, but there is no universal “cure” — obesity is a chronic condition for many people and often requires ongoing management.

Safety, monitoring, and practical points

• Common side effects: nausea, vomiting, diarrhea, constipation, decreased appetite; these usually improve with dose escalation. Less common but important risks: gallbladder disease, pancreatitis, and (in animal studies) thyroid C‑cell tumors; they are contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
• People with diabetes need glucose monitoring and possible adjustment of insulin or sulfonylureas. Kidney function and dehydration should be watched if vomiting occurs.
• Cost/coverage: insurance coverage for obesity medications varies widely. Wegovy and Zepbound are FDA‑approved for chronic weight management, but coverage by insurers may be limited.

Practical recommendations

• Talk with an obesity‑medicine clinician or your primary care provider before starting. Look for an ABOM‑certified (American Board of Obesity Medicine) clinician for specialized care.
• Expect discussion of goals: a 5–15% weight loss is clinically meaningful; some medications can deliver more.
• Plan for long‑term follow‑up (diet/exercise support, side‑effect management, labs) and a strategy for maintenance whether you continue medication or not.

Brands/services to discuss with your clinician

• Wegovy (semaglutide): FDA‑approved for chronic weight management; strong evidence for ~10–15% average loss at ~1 year.
• Zepbound (tirzepatide): FDA‑approved for weight management (higher mean weight loss seen in trials than older GLP‑1s).
• Saxenda (liraglutide): older GLP‑1 used for weight, less potent than semaglutide/tirzepatide.
• Ozempic (semaglutide) and Mounjaro (tirzepatide): diabetes formulations sometimes used/off‑label in weight care under clinician direction.
• For care delivery: seek ABOM‑certified obesity medicine physicians or established multidisciplinary weight‑management clinics. Telemedicine services (e.g., some clinics like Ro, PlushCare, Hims & Hers — check local availability and credentials) can assist with access but verify licensing and follow‑up plans.

If you want, I can:

• Estimate a personalized timeline if you tell me your current weight, goals, and any medical conditions/medications.
• Help you prepare questions to ask a clinician or list ABOM resources/clinics in your area.